COVID-19 Impact: Dr Reddys, Wockhardt alter Rs 1850 crore deal terms

Subsequently, through an amendment to the BTA, Dr.Reddys and Wockhardt that 1,483 crore would be paid on the date of closing the deal consideration, and the rest would be through different ways, the release said.;

Published On 2020-06-11 05:36 GMT | Update On 2020-06-11 05:36 GMT

New Delhi: Dr.Reddy's Laboratories Ltd on Wednesday announced that it has completed the acquisition of select divisions of WockhardtNSE -0.06 % Limiteds branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.

The business comprises a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr Reddys along with related sales and marketing teams and a manufacturing plant located in Baddi, Himachal Pradesh with all plant employees, a press release from the drugmaker said.

On February 12, 2020, Dr.Reddys signed a Business Transfer Agreement(BTA) with Wockhardt to acquire the above- referred business undertaking for an upfront consideration of Rs 1,850 crore.

In view of the COVID-19 pandemic and the consequent government restrictions, there has been a reduction in the revenue from the sales of the products forming part of the Business Undertaking during March and April 2020, it said.

Subsequently, through an amendment to the BTA, Dr.Reddys and Wockhardt that 1,483 crore would be paid on the date of closing the deal consideration, and the rest would be through different ways, the release said.

G V Prasad, Co-Chairman and Managing Director of Dr. Reddys said this deal is in line with the companys strategic focus on India and has paved a path for accelerated growthand leadership in the domestic market.

"We believe that the acquired portfolio offers a good growth potential for us. We welcome the employees joining us from Wockhardt to the family of Dr.Reddys," Prasad said.

Also Read: India Ratings And Research Assigns A1-Plus Rating To Dr Reddy's Commercial Papers

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

COVID-19 Impact: Dr Reddys, Wockhardt alter Rs 1850 crore deal terms

Subsequently, through an amendment to the BTA, Dr.Reddys and Wockhardt that 1,483 crore would be paid on the date of closing the deal consideration, and the rest would be through different ways, the release said.;

Similar News

Gufic Biosciences appoints Rajesh Kaul as Senior President - Sparsh Cluster

Alembic buys UTI-focused Utility Therapeutics in USD 12 million deal

Biocon Biologics gets EU nod for bone disease treatments, including Osteoporosis, giant cell tumour of bone

Aurobindo Pharma arm gets marketing nod for Dazublys from European Commission

Lincoln Pharma to begin API production at Khatraj facility in 1- 2 years

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC

Delhi HC Rejects Modi-Mundipharma's Monopoly Claim Over 'CONTIN', Allows Limited Relief

Natco Pharma sees major leadership exit in RnD, demand & supply, quality